A Phase 3 interventional study of Celecoxib and Diclofenac SR in Ankylosing Spondylitis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.
Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 21st largest by enrollment of the 62 interventional ones that give a count, is the only one that started in 2009, is one of 18 in phase 3, and was the 3rd registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–75
Huabo Biopharm Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–70
China-Japan Friendship Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 22 · Phase 4 17
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 150 across the 62 interventional studies, 440 across the 14 observational. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 2 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
9 of the studies in Spondylitis, Ankylosing with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237568Phase 3Lynk Pharmaceuticals Co., LtdA Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | 2026-11 |
| NCT06000956Phase 3Tasly Pharmaceutical Group Co., LtdA Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | 2026-12-01 |
| NCT07261644Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | 2027-01-14 |
| NCT07172360Phase 3Jiangsu vcare pharmaceutical technology co., LTDEfficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | 2027-08-30 |
| NCT07920861Huabo Biopharm Co., Ltd.A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 76 studies in Spondylitis, Ankylosing with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Celecoxib
Drug: Diclofenac SR
capsule, 200 mg QD, 6-12 weeks
tablet, 75 mg QD,6-12 weeks
Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6
100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of less than (\<) 0 indicated improvement.
Time frame: Baseline, Week 6
Participant's Assessment of Global Pain Intensity at Baseline
100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain.
Time frame: Baseline
Change From Baseline in Participant's Assessment of Global Pain Intensity at Weeks 2 and 4
100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4
Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 12
100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of \<0 indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Participant's Global Assessment of Disease Activity at Weeks 2, 4, and 6
5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in Participant's Global Assessment of Disease Activity at Week 12
5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, and 6
5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12
5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, and 6
Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in BASFI at Week 12
BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Weeks 2, 4, and 6
Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in BASDAI at Week 12
BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Percentages of Participants Responding to Assessment in Ankylosing Spondylitis (ASAS)-20
Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).
Time frame: Weeks 2, 4, 6, 12
Change From Baseline in Nocturnal Pain at Weeks 2, 4, and 6
100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in Nocturnal Pain at Week 12
100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in Fingertips to Floor Distance at Weeks 2, 4, and 6
Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in Fingertips to Floor Distance at Week 12
Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline \<0 represented improvement.
Time frame: Baseline, Week 12
Change From Baseline in Chest Expansion at Weeks 2, 4, and 6
Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (\>) 0 represented improvement.
Time frame: Baseline, Weeks 2, 4, 6
Change From Baseline in Chest Expansion at Week 12
Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (\>) 0 represented improvement.
Time frame: Baseline, Week 12
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6
Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 6
Change From Baseline in ESR at Week 12
ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Change From Baseline in C-Reactive Protein (CRP) at Week 6
C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline \<0 indicated improvement.
Time frame: Baseline, 6 Weeks
Change From Baseline in CRP at Week 12
CRP was a marker of inflammation. Lower values indicated better health. Change from baseline \<0 indicated improvement.
Time frame: Baseline, Week 12
Percentage of Participants With Concomitant Use of Paracetamol
Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6
Time frame: Week 6
Percentage of Days With Concomitant Administration of Paracetamol
Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.
Time frame: Week 6
Paracetamol Tablets Taken Per Day by Participant
Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.
Time frame: Week 6
| Milestone | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Started | 120 | 120 | 0 | 0 |
| Completed | 113 | 110 | 0 | 0 |
| Not completed | 7 | 10 | 0 | 0 |
| Withdrew: Insufficient clinical response | 2 | 2 | 0 | 0 |
| Withdrew: No longer willing to participate | 3 | 4 | 0 | 0 |
| Withdrew: Adverse event | 2 | 4 | 0 | 0 |
| Milestone | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Started | 113 | 110 | 0 | 0 |
| Completed | 109 | 109 | 0 | 0 |
| Not completed | 4 | 1 | 0 | 0 |
| Withdrew: Did not sign 2nd informed consent form | 4 | 1 | 0 | 0 |
| Milestone | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Started | 55 | 55 | 54 | 54 |
| Completed | 52 | 54 | 50 | 52 |
| Not completed | 3 | 1 | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
| Withdrew: Insufficient clinical response | 1 | 1 | 0 | 1 |
| Withdrew: No longer willing to participate | 1 | 0 | 3 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
100-millimeter (mm) Visual Analog Scale (VAS) score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of less than (\<) 0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6 | -23.8 ± 1.98 | -27.1 ± 2.02 |
100-mm VAS scores specified participant's assessment of global pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Participant's Assessment of Global Pain Intensity at Baseline | 62.9 ± 12.68 | 63.6 ± 13.38 |
100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Change from baseline of \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=116, 115) | -18.6 ± 1.78 | -17.9 ± 1.79 |
| Week 4 (n=117, 115) | -20.7 ± 1.86 | -23.3 ± 1.89 |
100-mm VAS score specified participant's assessment of overall pain intensity in the previous 48 hours, in response to the following question "What has been your global pain intensity in the last 48 hours?" 0=no pain to 100=worst pain. Lower scores indicated less pain. Change from baseline of \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 63.4 ± 13.58 | 61.1 ± 13.08 | 63.4 ± 12.05 | 65.6 ± 13.26 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -28.4 ± 21.39 | -30.9 ± 24.24 | -20.8 ± 21.86 | -28.1 ± 25.96 |
5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.
| units on a scale | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=116, 115) | -0.4 ± 0.06 | -0.4 ± 0.06 |
| Week 4 (n=117, 115) | -0.3 ± 0.06 | -0.4 ± 0.06 |
| Week 6 (n=117, 115) | -0.3 ± 0.06 | -0.4 ± 0.06 |
5-point Likert scale scores specified participant's current situation in response to the following question "Considering all the ways your Ankylosing Spondylitis affects you, how are you doing today?" 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.
| units on a scale | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 3.1 ± 0.83 | 3.0 ± 0.64 | 3.2 ± 0.66 | 3.2 ± 0.70 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -0.6 ± 0.99 | -0.6 ± 0.78 | -0.4 ± 0.71 | -0.6 ± 0.96 |
5-point Likert scale scores specified physician's subjective assessment on how overall ankylosing spondylitis appeared at the time of participant's visit and participant's disease signs. 1=very good to 5=very poor. Change from baseline \<0 indicated improvement.
| units on a scale | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=116, 115) | -0.4 ± 0.05 | -0.4 ± 0.05 |
| Week 4 (n=117, 115) | -0.4 ± 0.05 | -0.5 ± 0.05 |
| Week 6 (n=117, 115) | -0.5 ± 0.06 | -0.5 ± 0.06 |
5-point Likert scale scores specified physician's subjective assessment on how the overall ankylosing spondylitis appeared at the time of the participant's visit and participant's disease signs. 1=very good to 5=very poor. Lower scores indicated better health. Change from baseline \<0 indicated improvement.
| units on a scale | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 3.2 ± 0.57 | 3.0 ± 0.45 | 3.2 ± 0.43 | 3.3 ± 0.50 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -0.7 ± 0.60 | -0.5 ± 0.64 | -0.5 ± 0.51 | -0.7 ± 0.75 |
Bath Ankylosing Spondylitis Functional Index (BASFI) was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Change from baseline \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=116, 115) | -0.3 ± 0.13 | -0.3 ± 0.13 |
| Week 4 (n=117, 115) | -0.4 ± 0.14 | -0.6 ± 0.14 |
| Week 6 (n=117, 115) | -0.5 ± 0.15 | -0.8 ± 0.15 |
BASFI was comprised of 10 specific questions, each answered on a 10-mm VAS scale. 0=easy to 10=impossible. BASFI score was defined as the mean of the scaled responses to these 10 questions. Lower scores indicated better functional health. Change from baseline \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 3.4 ± 1.98 | 3.5 ± 2.13 | 3.5 ± 1.83 | 3.5 ± 2.25 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -0.9 ± 1.78 | -1.0 ± 1.64 | -0.6 ± 1.97 | -1.0 ± 2.30 |
Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was comprised of 6 specific questions, each answered on a 10-mm VAS scale. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Change from baseline \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=116, 115) | -0.8 ± 0.14 | -0.9 ± 0.14 |
| Week 4 (n=117, 115) | -0.9 ± 0.15 | -1.1 ± 0.15 |
| Week 6 (n=117, 115) | -1.1 ± 0.16 | -1.4 ± 0.16 |
BASDAI is comprised of 6 specific questions, each answered on a 10-mm VAS. Scores for the first 5 questions: 0=none to 10=severe. Score for the sixth question: 0=0 hours to 10=2 hours. BASDAI score was defined as the mean of the scaled responses to these 6 questions. Lower scores indicated better health. Change from baseline \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 4.71 ± 1.79 | 4.9 ± 1.80 | 4.7 ± 1.48 | 4.9 ± 1.88 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -1.7 ± 1.86 | -2.1 ± 1.94 | -0.6 ± 1.87 | -1.4 ± 2.14 |
Percentages of participants who demonstrated an improvement of greater than or equal to (≥) 20% from baseline and an absolute improvement of ≥10 mm from baseline on a 100-mm VAS in ≥3 of the 4 domains proposed by the Ankylosing Spondylitis Assessment Working Group (ASAS-20).
| percentage of participants | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Week 2 (n=115, 114) | 23.5 | 25.4 | 0 | 0 |
| Week 4 (n=116, 114) | 26.7 | 31.6 | 0 | 0 |
| Week 6 (n=54, 54, 54, 54) | 40.7 | 42.6 | 22.2 | 29.6 |
| Week 12 (n=51, 53, 46, 51) | 49.0 | 47.2 | 32.6 | 37.3 |
100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Change from baseline \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=116, 115) | -12.0 ± 1.90 | -16.3 ± 1.91 |
| Week 4 (n=117, 115) | -14.5 ± 1.94 | -17.1 ± 1.96 |
| Week 6 (n=117, 115) | -15.4 ± 1.95 | -19.4 ± 1.98 |
100-mm VAS scores specified participant's nocturnal pain in response to the following question "Did you have any pain in the neck, back or hips during the previous night?" 0=no pain to 100=worst pain possible. Lower scores indicated less pain. Change from baseline \<0 indicated improvement.
| mm | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 52.2 ± 20.45 | 55.1 ± 19.24 | 54.5 ± 20.14 | 61.5 ± 19.17 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -19.4 ± 22.54 | -27.5 ± 25.62 | -12.5 ± 20.31 | -22.6 ± 30.36 |
Fingertips to floor distance measured in centimeter (cm) from the tip of the fingers to the floor with participants standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Change from baseline \<0 indicated improvement.
| cm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=117, 115) | -1.6 ± 0.62 | -1.6 ± 0.62 |
| Week 4 (n=118, 115) | -1.9 ± 0.69 | -2.2 ± 0.71 |
| Week 6 (n=118, 115) | -2.8 ± 0.67 | -3.1 ± 0.69 |
Fingertips to floor distance measured in cm from the tip of the fingers to the floor with participant standing erect and feet together, knees as straight as possible, then bending forward as far as possible with fingers reaching towards the floor. The better of 2 tries was recorded. Lower scores indicated better health. Change from baseline \<0 represented improvement.
| cm | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 14.8 ± 12.89 | 17.6 ± 15.23 | 22.9 ± 19.49 | 14.6 ± 14.48 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | -3.0 ± 9.38 | -3.7 ± 6.82 | -3.1 ± 8.18 | -1.3 ± 7.75 |
Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Change from baseline greater than (\>) 0 represented improvement.
| cm | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Week 2 (n=117, 115) | 0.2 ± 0.08 | 0.3 ± 0.08 |
| Week 4 (n=118, 115) | 0.6 ± 0.09 | 0.4 ± 0.09 |
| Week 6 (n=118, 115) | 0.7 ± 0.10 | 0.6 ± 0.10 |
Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (\>) 0 represented improvement.
| cm | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=55, 55, 54, 54) | 3.9 ± 1.93 | 3.8 ± 1.63 | 3.6 ± 1.82 | 3.8 ± 1.62 |
| Change from Baseline at Week 12 (n=52, 54, 46, 51) | 0.8 ± 1.26 | 0.8 ± 1.39 | 0.8 ± 1.29 | 0.8 ± 1.02 |
Erythrocyte Sedimentation Rate (ESR) was a laboratory test that providee a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h). Change from baseline \<0 indicated improvement.
| mm/h | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 6 | -2.5 ± 1.30 | -1.8 ± 1.30 |
ESR was a laboratory test that provided a non-specific measure of inflammation. The test assessed the rate at which red blood cells fell in a test tube. Lower values indicated better health. Change from baseline \<0 indicated improvement.
| mm/h | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=54, 54, 52, 54) | 20.9 ± 14.60 | 20.8 ± 18.98 | 22.8 ± 21.99 | 23.6 ± 19.64 |
| Change from Baseline at Week 12 (n=45, 44, 41, 43) | -3.5 ± 13.96 | -1.3 ± 11.14 | -6.3 ± 13.46 | -0.7 ± 19.47 |
C-Reactive Protein (CRP) was a marker of inflammation, measured in milligram per liter (mg/L). Change from baseline \<0 indicated improvement.
| mg/L | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Change From Baseline in C-Reactive Protein (CRP) at Week 6 | -4.16 ± 1.587 | -2.72 ± 1.600 |
CRP was a marker of inflammation. Lower values indicated better health. Change from baseline \<0 indicated improvement.
| mg/L | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|
| Baseline (n=53, 55, 53, 54) | 18.53 ± 28.749 | 15.84 ± 20.464 | 18.80 ± 25.774 | 21.01 ± 21.360 |
| Change from Baseline at Week 12 (n=47, 49, 42, 47) | -4.58 ± 9.682 | -2.99 ± 13.242 | -4.77 ± 24.656 | -2.13 ± 20.879 |
Percentage of participants who concomitantly took at least 1 paracetamol tablet as rescue medication at Week 6
| percentage of participants | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Percentage of Participants With Concomitant Use of Paracetamol | 2.5 | 0.0 |
Calculated as days on rescue medication divided by days of exposure in the study at the end of Week 6.
| percentage of days | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Percentage of Days With Concomitant Administration of Paracetamol | 0.1 ± 0.08 | 0.0 ± 0.00 |
Calculated as the total number of paracetamol tablets taken divided by days of exposure in the study.
| tablets per day | Celecoxib 200 mg | Diclofenac SR 75 mg |
|---|---|---|
| Paracetamol Tablets Taken Per Day by Participant | 0.2 ± 0.16 | 0.0 ± 0.00 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Celecoxib 200 mg | — | 0/120 (0%) | 11/120 (9.2%) |
| Diclofenac SR 75 mg | — | 0/120 (0%) | 9/120 (7.5%) |
| Celecoxib 200 mg, Then Celecoxib 200 mg | — | 0/54 (0%) | 0/54 (0%) |
| Diclofenac SR 75 mg, Then Diclofenac SR 75 mg | — | 0/55 (0%) | 6/55 (10.9%) |
| Celecoxib 200 mg, Then Celecoxib 400 mg | — | 0/53 (0%) | 5/53 (9.4%) |
| Diclofenac SR 75 mg, Then Celecoxib 400 mg | — | 0/54 (0%) | 6/54 (11.1%) |
| Event | Celecoxib 200 mg | Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 200 mg | Diclofenac SR 75 mg, Then Diclofenac SR 75 mg | Celecoxib 200 mg, Then Celecoxib 400 mg | Diclofenac SR 75 mg, Then Celecoxib 400 mg |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/120 | 1/120 | 0/54 | 0/55 | 0/53 | 2/54 |
| Alanine aminotransferase increasedInvestigations | 0/120 | 0/120 | 0/54 | 2/55 | 1/53 | 2/54 |
| BronchitisInfections and infestations | 0/120 | 0/120 | 0/54 | 0/55 | 1/53 | 0/54 |
| Transaminases increasedInvestigations | 0/120 | 0/120 | 0/54 | 1/55 | 1/53 | 0/54 |
| Weight decreasedInvestigations | 0/120 | 0/120 | 0/54 | 0/55 | 1/53 | 0/54 |
| White blood cell count decreasedInvestigations | 0/120 | 0/120 | 0/54 | 0/55 | 1/53 | 0/54 |
| Abdominal painGastrointestinal disorders | 0/120 | 0/120 | 0/54 | 0/55 | 0/53 | 1/54 |
| Hepatic function abnormalHepatobiliary disorders | 0/120 | 2/120 | 0/54 | 1/55 | 0/53 | 1/54 |
| AnaemiaBlood and lymphatic system disorders | 0/120 | 0/120 | 0/54 | 1/55 | 0/53 | 0/54 |
| Aspartate aminotransferase increasedInvestigations | 0/120 | 0/120 | 0/54 | 1/55 | 0/53 | 0/54 |
| Age, Customized(participants) | Celecoxib 200 mg | Diclofenac SR 75 mg | Total |
|---|---|---|---|
| 18 - 44 years | 109 | 109 | 218 |
| 45 - 64 years | 11 | 11 | 22 |
| Sex: Female, Male(Participants) | Celecoxib 200 mg | Diclofenac SR 75 mg | Total |
|---|---|---|---|
| Female | 15 | 19 | 34 |
| Male | 105 | 101 | 206 |
The record gives a start of Jul 2009, a primary completion of Jun 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →